
Annual report 2025
added 03-06-2026
IRadimed Corporation Revenue 2011-2026 | IRMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue IRadimed Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83.8 M | 73.2 M | 65.6 M | 53.3 M | 41.8 M | 31.7 M | 38.5 M | 30.4 M | 23.1 M | 32.5 M | 31.6 M | 15.7 M | 11.3 M | 7.69 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 83.8 M | 7.69 M | 38.6 M |
Quarterly Revenue IRadimed Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.2 M | 20.4 M | 19.5 M | - | 18.3 M | 17.9 M | 17.6 M | - | 16.5 M | 16.1 M | 15.5 M | - | 13.4 M | 12.7 M | 12.3 M | - | 10.9 M | 9.81 M | 9.22 M | - | 7.7 M | 6.79 M | 8.68 M | - | 9.96 M | 9.23 M | 8.44 M | - | 7.61 M | 7.38 M | 7.11 M | - | 5.69 M | 5.52 M | 5.16 M | - | 7.67 M | 9.87 M | 8.96 M | - | 8.19 M | 7.61 M | 6.99 M | - | 3.81 M | 4.7 M | 3.56 M | - | 2.48 M | 2.78 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 M | 2.48 M | 10.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.1 | -0.72 % | $ 314 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Electromed
ELMD
|
64 M | $ 25.81 | 0.98 % | $ 218 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.16 | - | $ 1.31 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.45 | 3.29 % | $ 129 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | -2.42 % | $ 38 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 11.53 | 4.63 % | $ 413 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 57.59 | -2.51 % | $ 3.14 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.48 | -1.44 % | $ 65.5 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 167.53 | -2.25 % | $ 11.8 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 48.25 | -12.02 % | $ 1.42 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.05 | -3.23 % | $ 17.8 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.42 | - | $ 6.71 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.04 | 7.98 % | $ 400 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.82 | -0.52 % | $ 1.02 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
TransMedics Group
TMDX
|
605 M | $ 94.93 | -2.21 % | $ 3.23 B | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 19.42 | -2.26 % | $ 1.32 B | ||
|
Globus Medical
GMED
|
2.94 B | $ 90.03 | -0.63 % | $ 12.2 B | ||
|
NanoVibronix
NAOV
|
2.55 M | - | - | $ 1.08 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.64 | 2.12 % | $ 1.14 B | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 295.25 | 1.5 % | $ 113 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.85 | 2.26 % | $ 2.98 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 82.91 | -0.5 % | $ 48.5 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.27 | -4.51 % | $ 51.7 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.64 | 0.83 % | $ 538 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.88 | 1.69 % | $ 36.8 M |